


VACCINE DEVELOPMENT

HSV-2 INFECTION MODELS

- Intravaginal inoculation of HSV-2 virus to monitor morbidity (clinical score & body weight loss), mortality and viral load during primary and recurrent phases in both female mice and guinea pigs* *
- HSV-2 infection model in male guinea pig
- Evaluate systemic and mucosal immune responses and protection
- Investigate latency and recurrence using clinical scores

LCMV INFECTION MODELS

- LCMV Clone 13: Chronic viral infection model used to study T cell exhaustion
- LCMV Armstrong: Acute viral infection model used to study immune responses
- Evaluation of viral titers through plaque assay
- Evaluation of pathogen-specific T cells using multi-color flow cytometry



HISTORICAL INFECTION MODELS

- Influenza A/PR8 (H1N1)
- Respiratory Syncytial Virus (RSV)
- Herpes Simplex Virus 1 (HSV-1)

VIRAL CAPABILITIES

- ABSL-2+ facilities for small animal studies
- ABSL-2 facilities for large animal studies
- Humanized mouse models available
- Customized virus infection models for clients



RESOURCES

Visit our website to access additional supportive materials.

WHITE PAPERS

- Oncolytic Viruses: A Multi-Pronged Approach to Tumor Killing
- How Sea Squirts can Hold the Key to Treating Covid-19
- How a Language Processing Model can Predict Mutations in Viruses

WEBINARS

- Casey Maguire, Harvard Medical School – Strategies for *in vivo* Barriers to Gene Therapy Vectors
- Jeffrey Vick, Chameleon Biosciences Inc. – Chameleon’s EVADER Technology: A more potent AAV vector with less immune response
- Miguel Muñoz-Alía, Mayo Clinic – Retargeting and Shielding Measles Virus Vectors for Oncolytic Virotherapy

ARTICLES

A mucosal vaccination approach for herpes simplex virus type 2.
Tirabassi, R.S., Ace, C., Levchenko, T.S., Torchilin, V.P., Selin, L.K., Nie, S., Guberski D.L., Yang, K. *Vaccine* 29 (2011) 1090–1098.


Mucosal vaccines against respiratory syncytial virus Kejian Yang and Steven M Varga; *Current Opinion in Virology* 2014, 6:78–84.



© Biomere, 2021

IT'S PERSONAL.

Driven to expedite your journey.



“ Herpes Simplex Virus (HSV) infections cause latency and recurrence which can lead to painful sores, virus shedding and transmission throughout a person’s life. Biomere has worked for over a decade on developing a mucosal HSV vaccine. This work and the research on a mucosal RSV vaccine has helped us build a strong service program on vaccine evaluation and infectious disease infection models. With extensive experience in several different viral model systems, we can find and set up the right virus model for your needs. ”

- Elizabeth O., Scientist